Loading…
← CockpitCompetitor Analysis › MANE Veradermics, IncorporatedOpen in the cockpit ↗

Veradermics, IncorporatedMANECompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Dermatology-focused pharmaceutical company; specific pipeline and commercial products not confidently known from public knowledge.

Momentum leader 83
Mkt cap
$5.27B
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$86.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.4%
Hurdle
n/a
no reverse DCF
Next earnings
138 days
5 Apr 2027
Close · USD$124.86
1D-0.6%
1W-20.2%
1M-1.8%
3M+18.6%
6M+18.6%
YTDn/a
1Yn/a
ATR %7.2%
52w lowhigh20.3% off high

What Veradermics does

Dermatology-focused pharmaceutical company; specific pipeline and commercial products not confidently known from public knowledge.

Where it sits in the supply chain

  • Pharmaceuticals
  • Dermatology

Moat: none

Employees: 21

Named competitors

Veradermics at a glance

Size Veradermics (MANE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.27B, the 1140th largest of 3,085 United States companies the cockpit tracks. Shares closed at $124.86 on 18 Nov 2026.

Performance Over six months the shares gained 18.6%, against +2.9% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Short interest Short interest is 8.1% of the free float (30 Oct 2026).

Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026MANE 119Peer median 103
Six months, rebased to 100: Veradermics against the median of its 20 peers (local-currency closes).

Veradermics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenue$0$0$0$0
Revenue growth————
Gross profit$0$0$0$0
EBITDAn/a-$72.3M-$26.8M-$17.3M
Net income-$93.6M-$70.0M-$26.5M-$16.5M
Free cash flown/a-$71.6M-$23.7M-$13.5M
Capital expendituren/a$24,000$0$0
Total debt$371,000$4,000$0$786,000

Quarterly statements and history in the cockpit →

Veradermics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%6885784506LQDA326030PTCTIPCALAB603087GLANDERASGLAXOABBOTINDIAEMCURELGNDSUPNMIRM9995IONSMANE6-month return →1-month return →
Up and to the right = strong over both horizons. Veradermics is the large dot.

Veradermics competitors and peer comparison

Head to head with its named competitors (MANE vs HIMS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Veradermics MANE$5.27B+19%n/an/an/an/a
Hims & Hers Health HIMS$4.00B-26%+30%-1%1.7×n/a

How Veradermics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Veradermics against its 20 peers (data as of 18 Nov 2026)
MeasureMANEPeer medianRank in peer set
1-month return-1.8%-2.1%11th highest of 21
6-month return+18.6%+2.9%5th highest of 21
Distance from 52-week high-20.3%-31.1%8th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%4.8×0.1%+519.6%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%1.9×1.7%-2.6%
Liquidia LQDAUnited States$5.08B-9%+798%47%7.8×5.0%+192.5%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%6.8×-4.4%+93.6%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%3.1×6.6%+35.4%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%4.6×16.5%+12.2%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%7.6×n/an/a
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%2.2×1.7%+6.2%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%1.6×-8.8%+3.0%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%7.1×20.2%+13.3%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%7.6×17.3%+19.9%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%10.2×26.4%+5.5%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%7.3×8.0%+10.0%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%4.5×15.9%+12.7%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%26.3×57.7%+7.5%
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%4.5×6.2%+13.9%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%9.6×n/an/a
RemeGen 9995.HKHong Kong$6.07B-28%+293%61%4.4×-6.8%+57.9%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%5.0×n/an/a

Questions

Who are Veradermics's main competitors?
Named competitors: Hims & Hers Health (HIMS), Cosmo Pharmaceuticals (private or unlisted). The cockpit's measured peer set (industry) also includes Shanghai Allist Pharmaceuticals (688578.SS), Sumitomo Pharma (4506.T), Liquidia (LQDA), SKBP (326030.KS), PTC Therapeutics (PTCT), IPCA Laboratories (IPCALAB.NS).
How has Veradermics stock performed?
Over six months to 18 Nov 2026 the shares returned +18.6% against +2.9% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.